Alere NMP22 BladderChek Test

System, Test, Tumor Marker, For Detection Of Bladder Cancer

FDA Premarket Approval P940035 S013

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Additional vendor for the goat anti-mouse lgg antibody used in the manufacture of the alere nmp22® bladderchek® test procedural control line.

DeviceAlere NMP22 BladderChek Test
Classification NameSystem, Test, Tumor Marker, For Detection Of Bladder Cancer
Generic NameSystem, Test, Tumor Marker, For Detection Of Bladder Cancer
ApplicantALERE SCARBOROUGH, INC
Date Received2016-08-16
Decision Date2016-09-08
PMAP940035
SupplementS013
Product CodeNAH
Advisory CommitteeImmunology
Supplement Type30-day Notice
Supplement ReasonProcess Change - Manufacturer/sterilizer/packager/supplier
Expedited ReviewNo
Combination Product No
Applicant Address ALERE SCARBOROUGH, INC 10 Southgate Road scarborough, ME 04074

Supplemental Filings

Supplement NumberDateSupplement Type
P940035Original Filing
S017 2022-02-08 Normal 180 Day Track No User Fee
S016 2021-05-27 30-day Notice
S015 2018-04-18 30-day Notice
S014 2017-01-30 30-day Notice
S013 2016-08-16 30-day Notice
S012 2016-04-06 30-day Notice
S011 2015-07-01 30-day Notice
S010 2013-07-10 Special (immediate Track)
S009 2013-03-18 30-day Notice
S008 2010-11-22 Normal 180 Day Track No User Fee
S007 2011-07-27 Normal 180 Day Track No User Fee
S006 2011-05-11 Normal 180 Day Track No User Fee
S005 2008-05-16 Normal 180 Day Track No User Fee
S004 2008-03-27 Normal 180 Day Track No User Fee
S003 2002-09-16 Normal 180 Day Track
S002 1999-07-23 Panel Track
S001 1996-12-16 Normal 180 Day Track

NIH GUDID Devices

Device IDPMASupp
10811877010637 P940035 000
10811877010545 P940035 000

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.